6 reports

THE DRUG CANDIDATE IS A ## MER PEPTIDE ACTS BY TARGETING PROGRAMMED CELL DEATH ## LIGAND ## (PD-L##).

  • Antibiotic Resistance
  • Blood Disease
  • Cell Therapy
  • Therapy
  • Bristol-Myers Squibb Company

Out of these ## drugs, only one of the drugs is generally approved.

  • Antibiotic Resistance
  • World
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Merck & Co., Inc.

THE DRUG CANDIDATE IS A ## MER PEPTIDE ACTS BY TARGETING PROGRAMMED CELL DEATH ## LIGAND ## (PD-L##).

  • Antibiotic Resistance
  • Blood Disease
  • Cell Therapy
  • Therapy
  • Bristol-Myers Squibb Company

Two out of the six were considered possibly related to study drug: one in Group ## and one in Group ##.

  • Antibiotic Resistance
  • Antifungal
  • United States
  • Product Initiative
  • SCYNEXIS, Inc.

Two out of the six were considered possibly related to study drug: one in Group ## and one in Group ##.

  • Antibiotic Resistance
  • Research And Development
  • United States
  • Product Initiative
  • SCYNEXIS, Inc.

allergy testing, drugs-of-abuse testing, therapeutic drug monitoring testing, microbiology, anatomical pathology, as well as environmental monitoring and process control.

  • Antibiotic Resistance
  • Biotech Diagnostics
  • Blood Supply
  • Molecular Diagnostics
  • Biocartis S.A.